A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia

NCT07722728 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: 30 mg B2227
DRUG: 70 mg B2227
DRUG: 150 mg B2227
DRUG: Vraylar® 1.5 mg
DRUG: Vraylar® 3.0 mg
DRUG: Vraylar® 4.5 mg
DRUG: Vraylar® 6.0 mg

Sponsor

Bostal Drug Delivery Co., Ltd